Basic research in renal tumours: Gene profiling and molecular markers

Location: Room 14c (ICM, Level 1)
Chairs: L. Mengual, Barcelona (ES)  
A. Vuksanovic, Belgrade (RS)

Aims and objectives of this presentation
To show and discuss latest advances in gene profiling as well as molecular markers of prognosis.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

217
Identifying the metastatic subclone by exhaustive sampling of primary and metastasis in clear cell renal cell carcinoma (ccRCC) pair

Institutes: 1Guy's and St' Thomas NHS Foundation Trust, Dept. of Oncology, London, United Kingdom, 2Guy's and St' Thomas NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 3Royal Marsden Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 4The Francis Crick Institute, Translational Cancer Therapeutics Laboratory, London, United Kingdom, 5Cruces University Hospital, Dept. of Pathology, Bilbao, Spain, 6Guy's and St' Thomas NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, 7Guy's and St' Thomas NHS Foundation Trust, Dept. of Medical Oncology, London, United Kingdom, 8The Francis Crick Institute, Advanced Sequencing Facility, London, United Kingdom

218
Intermittent hypoxia increases tumor angiogenesis in a mouse model of kidney cancer
By: Vilaseca Cabo A., Musquera M., Torres M., Campillo N., Gozal D., Montserrat J., Touijer K., Farré R., Almendros I., Alcaraz A.

Institutes: 1Hospital Clinic De Barcelona, Dept. of Urology, Barcelona, Spain, 2Universitat De Barcelona, Dept. of Biophysics and Bioengineering, Barcelona, Spain, 3University of Chicago, Dept. of Sleep Disorders, Chicago, United States of America, 4Hospital Clinic De Barcelona, Dept. of Pneumology, Barcelona, Spain, 5Memorial Sloan-Kettering Cancer Center, Dept. of Urology, New York, United States of America

219
Quantification, culture and characterization of circulating endothelial progenitor cells in patients with renal cell carcinoma
By: Yang B., Gu W., Sun W., Guo C., Yao X., Zheng J.

Institutes: Shanghai Tenth People's Hospital, Tongji University School Of Medicine, Dept. of Urology, Shanghai, China

220
Tumour-derived vascular endothelial growth factor mobilizes circulating endothelial progenitor cells and contributes to vasculogenesis of renal cell carcinoma
By: Yang B., Gu W., Guo C., Sun W., Che J., Liu M., Yao X., Zheng J.

Institutes: Shanghai Tenth People's Hospital, Tongji University School of Medicine, Dept. of Urology, Shanghai, China

221
Multi-region whole exome sequencing reveals monoclonal nature of inferior vena cava tumour thrombus extension in clear cell renal cell carcinoma
Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells is associated with poor prognosis in clear cell renal cell carcinoma

By: Stares M.¹, Nicol D.², O’Brien T.³, Challacombe B.³, Rowan A.¹, Horswell S.⁴, Salm M.⁴, Soultaï A.⁵, Hazell S.⁶, Chandra A.⁷, López J.⁸, Fisher R.⁹, Chowdhury S.⁵, Rudman S.⁵, Gore M.⁹, Larkin J.⁹, Matthews N.¹⁰, Turajlic S.¹, Swantow C.¹

Institutes: The Francis Crick Institute, Translational Cancer Therapeutics Laboratory, London, United Kingdom, ²Royal Marsden Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³Guys and St Thomas’ NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁴The Francis Crick Institute, Dept. of Bioinformatics and Biostatistics, London, United Kingdom, ⁵Guys and St Thomas’ NHS Foundation Trust, Dept. of Medicine, London, United Kingdom, ⁶Royal Marsden Hospital NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, ⁷Guys and St Thomas’ NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, ⁸Cruces University Hospital, Dept. of Pathology, Bilbao, Spain, ⁹Royal Marsden Hospital NHS Foundation Trust, Dept. of Medicine, London, United Kingdom, ¹⁰The Francis Crick Institute, Advanced Sequencing Facility, London, United Kingdom

Identification and validation of soluble carrier family expression signature for predicting poor outcome of renal cell carcinoma

By: Wan F., Ma C., Zhang H., Shi G., Zhu Y., Ye D.

Institutes: Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

Genetic alterations in specific chromosomal regions indicate metastatic potential in ccRCC patients

By: Grimm J.¹, Janssen M.¹, Hartmann A.², Kunath F.³, Stöhr C.², Stöckle M.¹, Junker K.¹

Institutes: UKS Universitätsklinikum des Saarlandes, Dept. of Urology and Pediatric Urology, Homburg/Saar, Germany, ²University Hospital Erlangen, Dept. of Pathology, Erlangen, Germany, ³University Hospital Erlangen, Dept. of Urology, Erlangen, Germany

Identification and validation of an 8-gene expression signature for predicting high Fuhrman grade renal cell carcinoma

By: Wan F.¹, Zhu Y.², Han C.², Xu Q.², Zhang H.², Shi G.², Gu W.², Ye D.²

Institutes: ¹Shanghai Medical College, Fudan University, Dept. of Oncology, Shanghai, China, ²Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

Myopodin methylation correlates to tumour progression and predicts antiangiogenic response in kidney cancer

By: Perez-Lonzac A.², Pompas-Veganzones N.², Beltran M³, Beardo P.⁴, Vazquez F.⁵, Cozar J.M.⁵, Alvarez-Ossorio J.L.⁶, Sanchez-Carbayo M.¹

Institutes: ¹University of the Basque Country, Bladder Cancer Group, Vitoria-Gasteiz, Spain, ²University of the Basque Country, Translational Oncology Lab, Vitoria-Gasteiz, Spain, ³Hospital Puerta Del Mar, Dept. of Pathology, Cadiz, Spain, ⁴Hospital De Jerez, Dept. of Urology, Cadiz, Spain, ⁵Hospital Virgen De Las Nieves, Dept. of Urology, Cadiz, Spain, ⁶Hospital Puerta Del Mar, Dept. of Urology, Cadiz, Spain

Circulating free genomic and mitochondrial DNA fragments and their diagnostic and prognostic potential in clear cell renal cell carcinoma patients

By: Ralla B.¹, Hongbiao L.², Jung M.³, Rabenhorst S.¹, Kilic E.¹, Budach N.², Fendler A.³, Jung K.³, Busch J.¹

Institutes: ¹Charité - Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ²Charité - Universitätsmedizin Berlin, Dept. of Radiology, Berlin, Germany
Predictive molecular biomarkers of renal clear cell carcinoma

Institutes: IRCCS Ospedale San Raffaele, Dept. of Oncology, Department of Urology, URI, Milan, Italy, IOR - Institute of Oncology Research, Lymphoma and Genomics Research Program Bioinformatics Core Unit, Bellinzona, Switzerland, Hospital of Cremona, Dept. of Oncology, Cremona, Italy, Institute of Cancer Research, Laboratory of Gastrointestinal Cancer Biology and Genomics, London, United Kingdom, University of Padua, Dept. of Pathology, Padua, Italy, IRCCS Ospedale San Raffaele, Division of Pathology, Milan, Italy, University of Padua, Dept. of Surgical Science, Milan, Italy

Significance of TERT variants in renal cell carcinoma

Institutes: Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York City, United States of America, Memorial Sloan Kettering Cancer Center, Dept. of Medicine, New York City, United States of America, Memorial Sloan Kettering Cancer Center, Dept. of Surgery, New York City, United States of America

Blood based exosomal miRNAs as biomarkers for diagnosis and prognosis of clear cell renal cell cancer
By: Heinzelmann J., Baumgart S., Hoelters S., Janssen M., Stöckle M., Junker K.

Institutes: Saarland University Medical Center, Dept. of Urology and Pediatric Urology, Hamburg, Germany, Saarland University Medical Center, Dept. of Urology and Pediatric Urology, Homburg, Germany